16133-46-3

Usage

Uses

Used in Pharmaceutical Industry:
6-Nitro-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid Methyl ester is utilized as a key intermediate in the synthesis of various pharmaceutical compounds for its potential role in creating antibacterial and antimalarial drugs. Its unique structure allows for the development of new molecules that can target and combat resistant strains of bacteria and parasites.
Used in Drug Development for Anti-Inflammatory Properties:
In the field of medicinal chemistry, 6-Nitro-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid Methyl ester is employed as a precursor in the creation of anti-inflammatory agents. Its structure is manipulated to produce compounds that can modulate inflammatory responses, offering potential therapeutic benefits for conditions characterized by chronic inflammation.
Used in Drug Development for Antioxidant Properties:
6-Nitro-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid Methyl ester is also used in the development of antioxidant drugs. Its potential to scavenge free radicals and protect cells from oxidative damage positions it as a valuable component in the formulation of medications aimed at combating oxidative stress-related diseases.
Used in Research and Development:
In the scientific community, 6-Nitro-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid Methyl ester serves as a subject of research for its chemical and biological properties. It is used to explore new avenues in drug discovery and to understand its interactions with biological systems, which can lead to the development of novel therapeutic agents.

Upstream product

• 16133-44-1 dimethyl 2-<(4-nitrophenyl)amino>-2-butenedioate 
• 100-01-6 4-nitro-aniline 
• 16133-44-1 methyl 3-carbomethoxy-3-(4'-nitrophenyl)amino-2-propenoate 
• 762-42-5 dimethyl acetylenedicarboxylate 
• 52962-22-8 (E)-2-(4-Nitro-phenylamino)-but-2-enedioic acid dimethyl ester 

Downstream Products

• 52979-42-7 methyl 6-amino-1,4-dihydro-4-oxo-2-quinolinecarboxylate 
• 169831-74-7 methyl 1,4-dihydro-1-methyl-6-<(4-methylbenzoyl)amino>-4-oxo-2-quinolinecarboxylate 
• 169831-77-0 methyl 4-methoxy-6-<(4-methylbenzoyl)amino>-2-quinolinecarboxylate 
• 169831-71-4 methyl 1,4-dihydro-6-<(4-methylbenzoyl)amino>-4-oxo-2-quinolinecarboxylate 
• 52980-10-6 6-amino-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid 
• 929028-74-0 6-acetylamino-4-oxo-1,4-dihydro-quinoline-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Novel vitexin-inspired scaffold against leukemia

Acute lymphoblastic leukemia (ALL) is the most common type of leukemia in children. Up to a quarter of ALL patients relapse and face poor prognosis. To identify new compound leads, we conducted a phenotypic screen using terrestrial natural product (NP) fr

Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists

A novel series of kynurenic acid amides, ring-enlarged derivatives of indole-2-carboxamides, was prepared and identified as in vivo active NR2B subtype selective NMDA receptor antagonists. The synthesis and SAR studies are discussed.

2-AMINOCARBONYL-QUINOLINE COMPOUNDS AS PLATELET ADENOSINE DIPHOSPHATE RECEPTOR ANTAGONISTS

Compounds of formula (I), where m, n, R1, R2, R3, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.

Platelet adenosine diphosphate receptor antagonists

Compounds of the following formula (I): where a, b, R1, R2, R4 and R6 are described herein, are useful as inhibitors of platelet adenosine diphosphate. Pharmaceutical compositions containing these compounds, met

Amide derivatives and nociceptin antagonists

The present invention relates to a compound of the formula [1′] wherein R2is lower alkyl optionally substituted by hydroxy, amino and the like, ring B is phenyl, thienyl and the like, E is a single bond, —O—, —S— and the like, ring G is aryl, heterocyclic group and the like, R5is halogen atom, hydroxy, lower alkyl optionally substituted by halogen atom etc., and the like, t is 0 or an integer of 1 to 5, when t is an integer of 2 to 5, each R5may be the same or different, m is 0 or an integer of 1 to 8, and n is 0 or an integer of 1 to 4, and a nociceptin antagonist containing compound [1′] as an active ingredient. The compound [1′] shows, due to nociceptin antagonistic action, analgesic effect against sharp pain such as postoperative pain and the like. The present invention also relates to the use of certain amide derivative inclusive of compound [1′] as a nociceptin antagonist or analgesic.

Kynurenic acid derivatives inhibit the binding of nerve growth factor (NGF) to the low-affinity p75 NGF receptor

The ability of a series of substituted kynurenic acids, thienopyridinonecarboxylic acids, and related compounds to inhibit the binding of nerve growth factor (NGF) to the p75 NGF receptor (NGFR) was evaluated in a radioligand binding assay that utilized a